Amryt Pharma's revenue per share for the
three
months ended in Sep. 2022 was $0.95.
Amryt Pharma's revenue per share for the trailing twelve months (TTM) ended in Sep. 2022 was $3.70.
Warning Sign:
Amryt Pharma PLC revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Amryt Pharma was -29.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 34.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 67.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Amryt Pharma's Revenue per Share or its related term are showing as below:
AMYT'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 34.2 Med: 40.8 Max: 144.8
Current: 34.2
During the past 12 years, Amryt Pharma's highest 3-Year average Revenue Per Share Growth Rate was 144.80% per year. The lowest was 34.20% per year. And the median was 40.80% per year.
AMYT's 3-Year Revenue Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.25
vs AMYT: 34.20
Amryt Pharma Revenue per Share Historical Data
The historical data trend for Amryt Pharma's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amryt Pharma's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amryt Pharma's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Amryt Pharma's PS Ratio falls into.
Amryt Pharma Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Amryt Pharma's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amryt Pharma (NAS:AMYT) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Amryt Pharma Revenue per Share Related Terms
Thank you for viewing the detailed overview of Amryt Pharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMYT has been successfully added to your 